Evidence map›Paper›PMID 35821265›Full record

SynthesisWorld journal of urology2022

Oncological and functional outcomes after testis-sparing surgery in patients with germ cell tumors: a systematic review of 285 cases.

Josias Bastian Grogg, Zeynep Hafza Dursun, Joerg Beyer, Daniel Eberli, Cedric Poyet, Thomas Hermanns, Christian Daniel Fankhauser

Open access · hybridAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in World journal of urology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Josias Bastian Grogg *Department of Urology, University of Zurich, Zurich, Switzerland.
Zeynep Hafza Dursun *Department of Urology, University of Zurich, Zurich, Switzerland.
Joerg BeyerDepartment of Oncology, Inselspital Bern, University of Bern, Bern, Switzerland.
Daniel EberliDepartment of Urology, University of Zurich, Zurich, Switzerland.
Cedric PoyetDepartment of Urology, University of Zurich, Zurich, Switzerland.
Thomas HermannsDepartment of Urology, University of Zurich, Zurich, Switzerland.
Christian Daniel FankhauserDepartment of Urology, University of Zurich, Zurich, Switzerland. cdfankhauser@gmail.com.ORCID http://orcid.org/0000-0002-4073-5488
University of Zurich · CHUniversity of Bern · CHUniversity of Lucerne · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

INTRODUCTION AND

objectivesIn several urogenital cancers, organ-preserving surgery represents the preferred treatment approach, but in patients with testicular germ cell tumors (tGCTs), radical orchiectomy represents the standard of care. This study aimed to summarize published case series assessing oncological and functional outcomes after testis-sparing surgery (TSS) in patients with tGCTs. MATERIALS AND

methodsA systematic literature review and individual patient data meta-analysis were conducted of published cases with tGCT treated with TSS.

resultsOf 2,333 reports, we included 32 reports providing data on 285 patients, including 306 testicles treated with TSS. Adjacent germ cell neoplasia in situ (GCNIS) was described in 43%. Hypogonadism and infertility after TSS were diagnosed in 27% and 18%. In patients undergoing adjuvant testicular radiotherapy, hypogonadism was diagnosed in 40%. Patients treated with adjuvant testicular radiotherapy after TSS exhibited a significantly lower incidence of local recurrence (2% vs. 50%, p < 0.001). Distant metastases after TSS were observed in 2%.

conclusionThe current data questions the benefits of TSS in tGCT patients. If at all, TSS should only be offered to well-informed patients with a singular testicle, excellent compliance, a singular tumor less than 2 cm located at the lower pole of the testicle, and normal preoperative endocrine function. Unless patients plan to father a child within a short time frame, adjuvant testicular radiotherapy should be recommended after TSS. Radical orchiectomy remains the standard of care, but future studies may support the use of TSS in selected men.

Indexed as

HypogonadismNeoplasms, Germ Cell and EmbryonalTesticular NeoplasmsHumansMaleOrchiectomyOrgan Sparing TreatmentsTestisSystematic reviewTestis cancerTestis-sparing surgeryUrology

Identifiers

PMID35821265
PMCPMC9427883
OpenAlexW4285089203

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.